Sumary of ATN framework can be extended to detect frontotemporal degeneration:
- Even so, the development of biomarkers can give patients and their families answers during life: Alzheimer’s disease can be accurately detected via peptides and proteins in a patient’s cerebrospinal fluids (CSF), which can be collected through a lumbar puncture and tested while the patient is alive.
- In 2018, a new framework suggested combining three Alzheimer’s disease biomarkers in CSF – pathologic amyloid plaques (A), tangles (T), and neurodegeneration (N), collectively called ATN.
- Biomarkers can fill the gap by providing evidence of whether Alzheimer’s pathology underlies a patient’s symptoms.
- CSF biomarkers work similarly to a pregnancy test, offering a simple positive or negative result when enough of a substance is detected.
- But like a pregnancy test, biomarkers for Alzheimer’s disease can provide false negatives or positives.
- However, to accomplish this, additional biomarkers that can detect other neurodegenerative conditions are critically needed.
- “While the ATN framework is very exciting and offers much opportunity for patients with Alzheimer’s disease, these biomarkers don’t capture every case of the disease.